Patents by Inventor Raymond G. Goodwin

Raymond G. Goodwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors
    Patent number: 5712155
    Abstract: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: January 27, 1998
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Use of interleukin-7 to stimulate proliferation of hematopoietic cell precursors
    Patent number: 5705149
    Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: January 6, 1998
    Assignee: Sterling Winthrop Inc.
    Inventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki
  • Antibodies directed against CD30 ligand
    Patent number: 5677430
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: October 14, 1997
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Cytokine designated 4-IBB ligand
    Patent number: 5674704
    Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.
    Type: Grant
    Filed: May 6, 1994
    Date of Patent: October 7, 1997
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Mark R. Alderson
  • CD27 ligand
    Patent number: 5573924
    Abstract: CD27 ligand (CD27L) polypeptide and DNA sequences, vectors and transformed host cells useful in providing CD27L polypeptides. The CD27L polypeptide binds to the CD27 receptor.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: November 12, 1996
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Raymond G. Goodwin, Judith G. Giri, Richard J. Armitage
  • Antibodies to interleuken-7 receptors
    Patent number: 5543320
    Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, antibodies to mammalian Interleukin 7 receptors and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: August 6, 1996
    Assignee: Immunex Corporation
    Inventors: Linda S. Park, Raymond G. Goodwin
  • CD30 ligand
    Patent number: 5480981
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: April 12, 1994
    Date of Patent: January 2, 1996
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Isolated viral protein TNF antagonists
    Patent number: 5464938
    Abstract: Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to cytokines, thereby functioning as cytokine antagonists. Also disclosed are processes for preparing isolated vital protein cytokine antagonists.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: November 7, 1995
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin
  • Cytokine which is a ligand for OX40
    Patent number: 5457035
    Abstract: There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: October 10, 1995
    Assignee: Immunex Corporation
    Inventors: Peter R. Baum, William C. Fanslow, III, Richard B. Gayle, Raymond G. Goodwin
  • DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors
    Patent number: 5395760
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 10, 1990
    Date of Patent: March 7, 1995
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Isolated poxvirus A53R-equivalent tumor necrosis factor antagonists
    Patent number: 5359039
    Abstract: Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to Tumor Necrosis Factor, thereby functioning as Tumor Necrosis Factor antagonists. Also disclosed are processes for preparing isolated viral protein cytokine antagonists.
    Type: Grant
    Filed: July 9, 1993
    Date of Patent: October 25, 1994
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin
  • Interleukin-7
    Patent number: 5328988
    Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: October 6, 1992
    Date of Patent: July 12, 1994
    Assignee: Immunex Corporation
    Inventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki
  • Interleukin-7 receptors
    Patent number: 5264416
    Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: June 1, 1992
    Date of Patent: November 23, 1993
    Assignee: Immunex Corporation
    Inventors: Linda S. Park, Raymond G. Goodwin
  • DNA encoding interleukin-7 receptors and methods of use
    Patent number: 5194375
    Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 21, 1990
    Date of Patent: March 16, 1993
    Assignee: Immunex Corporation
    Inventors: Linda S. Park, Raymond G. Goodwin
  • Interleukin-7
    Patent number: 4965195
    Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: October 7, 1988
    Date of Patent: October 23, 1990
    Assignee: Immunex Corp.
    Inventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki